, Tracking Stock Market Picks
Enter Symbol:
Alnylam Pharmaceuticals, Inc. (ALNY) [hlAlert]

up 555.21 %

Alnylam Pharmaceuticals, Inc. (ALNY) rated Buy by ThinkEquity

Posted on: Thursday,  May 20, 2010  8:25 AM ET by ThinkEquity

ThinkEquity rated Buy Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) on 05/20/2010, when the stock price was $16.01. Since
then, Alnylam Pharmaceuticals, Inc. has gained 555.22% as of 01/22/2016's recent price of $104.90.
If you would have followed this ThinkEquity's recommendation on ALNY, you would have gained 555.21% of your investment in 2073 days.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is building a pipeline of RNAi therapeutics; its lead program is in Phase I human clinical trials for the treatment of respiratory syncytial virus infection, which is the leading cause of hospitalization in infants in the U.S. The company's leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Merck, Medtronic, Novartis, and Biogen Idec.

Research is at the core of everything we do at ThinkEquity, and we're passionate about it. Employing a disciplined and rigorous process, we scrutinize the spectrum of forces at play in the growth sectors we cover. Starting with a top down analysis, we look closely at the megatrends and industry drivers that create opportunities for innovative companies. We then allocate our resources based on a long-range research roadmap that leads to deep domain expertise and a close working knowledge of the technologies, products, services and people that populate the growth sector landscape. In short, the sum result of the ThinkEquity research process is to identify and affiliate ourselves with the fastest growing private and public companies within our domain verticals.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/20/2010 8:25 AM Buy
as of 12/31/2010
1 Week up  8.27 %
1 Month up  15.84 %
3 Months down  -13.61 %
1 YTD down  -33.79 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy